Literature DB >> 1092608

Release of 14C label and complement killing of Escherichia coli.

B M Wilson, A A Glynn.   

Abstract

When Escherichia coli labelled with 14C were killed by complement, characteristic 14C compounds were released even when complete cell disintegration was prevented or delayed by removal of lysozyme. Treatment with heated serum only resulted in the loss of small molecular weight compounds. Separation of the products was made easier if whole serum was replaced by a salt-precipitated fraction which contained no albumin or lysozyme but retained antibody and complement. Fractionation of the bacterial products on Sephadex G-200 showed two radioactive peaks containing lipids and proteins of which a preliminary examination was made. The release of these compounds was related to complement action, since they were not found when bacteria were killed by streptomycin or ultra-violet light in the absence of complement. Nor were they found when resistant bacteria were treated with complement and survived. The possible modes of action of complement on bacterial cell walls are discussed.

Entities:  

Mesh:

Substances:

Year:  1975        PMID: 1092608      PMCID: PMC1445779     

Source DB:  PubMed          Journal:  Immunology        ISSN: 0019-2805            Impact factor:   7.397


  14 in total

1.  ACTIVITY OF THE ANTIBODY-COMPLEMENT SYSTEM AND LYSOZYME AGAINST ROUGH GRAM NEGATIVE ORGANISMS.

Authors:  L H MUSCHEL; J E JACKSON
Journal:  Proc Soc Exp Biol Med       Date:  1963 Aug-Sep

2.  SEPARATION OF HUMAN HEME- AND HEMOGLOBIN-BINDING PLASMA PROTEINS, CERULOPLASMIN AND ALBUMIN BY GEL FILTRATION.

Authors:  J KILLANDER
Journal:  Biochim Biophys Acta       Date:  1964-10-09

3.  Electrokinetic requirements for the reaction between Cl. perfringens alpha-toxin (phospholipase C) and phospholipid substrates.

Authors:  A D BANGHAM; R M DAWSON
Journal:  Biochim Biophys Acta       Date:  1962-05-07

4.  Phosphorus compounds in the cell. III. The incorporation of radioactive phosphorus into the ribonucleotide fraction of liver tissue.

Authors:  J N DAVIDSON; R M S SMELLIE
Journal:  Biochem J       Date:  1952-12       Impact factor: 3.857

5.  Complement and phospholipase C lysis of lipid membranes.

Authors:  T R Hesketh; S N Payne; J H Humphrey
Journal:  Immunology       Date:  1972-11       Impact factor: 7.397

6.  Action of pure phospholipase A 2 and phospholipase C on human erythrocytes and ghosts.

Authors:  B Roelofsen; R F Zwaal; P Comfurius; C B Woodward; L L van Deenen
Journal:  Biochim Biophys Acta       Date:  1971-09-14

7.  Characteristics of complement-dependent release of phospholipid from Escherichia coli.

Authors:  L A Wilson; J K Spitznagel
Journal:  Infect Immun       Date:  1971-07       Impact factor: 3.441

8.  Molecular analysis of the membrane attack mechanism of complement.

Authors:  W P Kolb; J A Haxby; C M Arroyave; H J Müller-Eberhard
Journal:  J Exp Med       Date:  1972-03-01       Impact factor: 14.307

9.  The complement-dependent bacteriolytic activity of normal human serum. I. The effect of pH and ionic strength and the role of lysozyme.

Authors:  A C WARDLAW
Journal:  J Exp Med       Date:  1962-06-01       Impact factor: 14.307

10.  The fate of bacteria within phagocytic cells. I. The degradation of isotopically labeled bacteria by polymorphonuclear leucocytes and macrophages.

Authors:  Z A COHN
Journal:  J Exp Med       Date:  1963-01-01       Impact factor: 14.307

View more
  3 in total

1.  Effect of some R factors on the sensitivity of rough Enterobacteriaceae to human serum.

Authors:  A Fietta; E Romero; A G Siccardi
Journal:  Infect Immun       Date:  1977-11       Impact factor: 3.441

2.  Determination of serum bactericidal activity with the aid of luminous bacteria.

Authors:  M Barak; S Ulitzur; D Merzbach
Journal:  J Clin Microbiol       Date:  1983-08       Impact factor: 5.948

3.  Sequential metabolic expressions of the lethal process in human serum-treated Escherichia coli: role of lysozyme.

Authors:  R J Martinez; S F Carroll
Journal:  Infect Immun       Date:  1980-06       Impact factor: 3.441

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.